Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia

Phase 4

Completed

Conditions: Depression
Dyspepsia
Compliance

Interventions: Drug: Flupentixol-Melitracen(without explanation) + Omeprazole
Drug: Flupentixol-Melitracen(psychological and GI) + Omeprazole
Drug: Flupentixol-Melitracen(psychological) + Omeprazole
Drug: Omeprazole

Registration Number: NCT01851863

Lead Sponsor: RenJi Hospital

Brief Summary: The study hypothesis is appropriate clinician-patient communication that provides explanations of the reasons for psychoactive drug prescriptions based on the generation of FD symptoms and the drugs' effects might improve compliance with psychoactive agent regimens among FD patients.

Detailed Description: Antidepressive agents have been proved to be effective in the treatment of functional dyspepsia (FD) patients. However, one of the factors that limit therapeutic benefit is the poor compliance with prescribed drugs. The possible reasons for lack of compliance include the patient's health beliefs (e.g., that people who took such agents is possibly considered insane in China), lack of knowledge about antidepressants (that they are addictive or can be stopped on recovery), and aversion to side effects. The investigators propose to examine whether different clinician-patient communication methods could affect adherence to antidepressant drugs in functional dyspepsia patients.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 262

Inclusion Criteria

met the ROME III criteria for FD;
education level no lower than high school;
Hospital Anxiety and Depression Scale (HADS) score > 8 respectively;
absence of abnormalities in physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), abdominal ultrasonography and upper GI endoscopy within 6 months;
absence of H. pylori infection

Exclusion Criteria

known allergy to omeprazole, flupenthixol or melitracen;
any evidence of organic digestive diseases;
reflux-related symptoms only (e.g., retrosternal pain, burning and regurgitation) or predominantly reflux-related symptoms;
severe psychological symptoms that affected life and work;
pregnancy or breastfeeding;
recent myocardial infarction or cardiac arrhythmias;
previous gastric surgery;
use of PPIs, psychoactive drugs or other drugs that might affect gastric function within 6 months

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Flupentixol-Melitracen(without explanation) + Omeprazole	Flupentixol-Melitracen(without explanation) + Omeprazole	In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
Flupentixol-Melitracen(psychological and GI) + Omeprazole	Flupentixol-Melitracen(psychological and GI) + Omeprazole	The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
Flupentixol-Melitracen(psychological) + Omeprazole	Flupentixol-Melitracen(psychological) + Omeprazole	The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
proton pump inhibitor	Omeprazole	Prescribe Omeprazole.

Primary Outcome Measures

Name	Time	Method
Compliance of Flupentixol-Melitracen	weeks 1, 2, 4, 8	The patients were asked to keep a diary to record their medication intake. At each visit (weeks 1, 2, 4, 8), the patient bring back the drug bottle and the diary, then the physician recorded the number of pills remaining in the bottle. Pills remained more than 20% at any visit or seven days of consecutive abstinence were adopted as the criterion for identifying therapy noncompliance.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Psychiatric Symptom on Hospital Anxiety and Depression Scale at Week 8	week 0 and 8	Each patient was surveyed using the Hospital Anxiety and Depression Scale to assess the psychiatric symptom at week 0 and 8.The HADS consists of 14 items, seven of which assess anxiety, and seven assess depression. The anxiety and depression subscales were calculated independently. The patients were asked to answer each item on a four-point (0 - 3) scale. Scores of 0 to 7 on either subscale can be regarded as within the normal range, scores of 8 to 10 are suggestive of the presence of the respective state, and scores of 11 or higher indicate the probable presence of the respective mood disorder. The change of HADS scores was calculated by HADS anxiety and depression scores of 8 weeks minus baseline, with lower values indicate better outcome.
Change From Baseline in Dyspepsia Symptom Questionnaire at Week 8	week 0 and 8	The severity of patients' dyspeptic symptoms were assessed using the Leeds Dyspepsia Questionnaire (LDQ) at week 0 and 8. The LDQ contains eight items about epigastric pain, retro-sternal pain, regurgitation, nausea, vomiting, belching, early satiety and dysphagia with six grades for each item and a sum of the eight symptom scores make the LDQ score.LDQ scores of 0 - 4 were classified as very mild dyspepsia, 4 - 8 as mild dyspepsia, 9 -15 as moderate dyspepsia, and \> 15 as severe or very severe dyspepsia. The change of LDQ scores was calculated by LDQ scores of 8 weeks minus baseline, with lower values represent a better outcome.